312 related articles for article (PubMed ID: 29516254)
1. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
2. The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
Fiore M; Sambri A; Spinnato P; Zucchini R; Giannini C; Caldari E; Pirini MG; De Paolis M
Curr Treat Options Oncol; 2021 Oct; 22(12):109. PubMed ID: 34687366
[TBL] [Abstract][Full Text] [Related]
3. Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Kojima Y; Shimoi T; Seo T; Yazaki S; Okuya T; Ohtake Y; Okuma HS; Shimomura A; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Tamura K; Yoshida A; Iwata S; Kobayashi E; Kawai A; Fujiwara Y; Yonemori K
Oncology; 2022; 100(7):370-375. PubMed ID: 35405680
[TBL] [Abstract][Full Text] [Related]
4. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
7. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Sharma S; Takyar S; Manson SC; Powell S; Penel N
BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
[TBL] [Abstract][Full Text] [Related]
9. Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Zanardi E; Maruzzo M; Montesco MC; Roma A; Rastrelli M; Basso U
Anticancer Drugs; 2014 Nov; 25(10):1227-30. PubMed ID: 25075796
[TBL] [Abstract][Full Text] [Related]
10. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
11. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Moreau-Bachelard C; Campion L; Toulmonde M; Le Cesne A; Brahmi M; Italiano A; Mir O; Piperno-Neumann S; Laurence V; Firmin N; Penel N; Duffaud F; Chevreau C; Bertucci F; Narciso B; Dubray-Longeras P; Delcambre C; Saada-Bouzid E; Boudou-Rouquette P; Soulie P; Perrin C; Blay JY; Bompas E
ESMO Open; 2022 Apr; 7(2):100402. PubMed ID: 35202953
[TBL] [Abstract][Full Text] [Related]
12. Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study.
Tian Z; Wang J; Yang J; Zhang P; Wang X; Zhang F; Li P; Yao W
Invest New Drugs; 2021 Dec; 39(6):1724-1731. PubMed ID: 34156595
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Grignani G; Martín-Broto J; Schuler M; Reichardt P
Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
[TBL] [Abstract][Full Text] [Related]
14. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).
Carroll C; Patel N; Gunsoy NB; Stirnadel-Farrant HA; Pokras S
Future Oncol; 2022 Oct; 18(32):3651-3665. PubMed ID: 36399116
[TBL] [Abstract][Full Text] [Related]
16. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
[TBL] [Abstract][Full Text] [Related]
17. Primary Pleural Synovial Sarcoma Treated with Pazopanib.
Sugitani A; Asai K; Kojima K; Eguchi Y; Kawaguchi T; Ohsawa M; Hirata K
Intern Med; 2015; 54(16):2051-5. PubMed ID: 26278301
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Salah S; Yaser S; Salem A; Al Mousa A; Abu Sheikha A; Sultan I
Med Oncol; 2013; 30(3):639. PubMed ID: 23780657
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
Spurrell EL; Fisher C; Thomas JM; Judson IR
Ann Oncol; 2005 Mar; 16(3):437-44. PubMed ID: 15653701
[TBL] [Abstract][Full Text] [Related]
20. A case of renal synovial sarcoma treated with adjuvant ifosfamide and doxorubicin.
Ozkan EE; Mertsoylu H; Ozardali HI
Intern Med; 2011; 50(15):1575-80. PubMed ID: 21804284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
